Close Menu

Precision Oncology News

The European Commission approved Merck's PD-1 inhibitor as a frontline therapy for this patient population based on the results of the Keynote-177 trial.

The SOPHIA trial reported median progression-free survival of 5.8 months for HER2-positive, metastatic breast cancer patients on margetuximab.

A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.